Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Johnson & Johnson: A Core Holding for the Long Haul

 

I have just written a report on JNJ in which I reiterated my Buy recommendation. I donít see a vibrant…
Read more…

Johnson & Johnson: A Buy and Core Holding for the Long Haul (JNJ, $68.35)

Investment Overview
Johnson & Johnson (JNJ) is a colossus among health care companies with an estimated $68 billion of revenues in…
Read more…

Quarterly Sales Show That Both Provenge and Zytiga Are Doing Very Well (DNDN, $13.58)

Investment Conclusion
Both Zytiga and Provenge have had very successful launches in the US. Fears that Zytiga would negatively impact sales…
Read more…

Johnson & Johnson's Turnaround Led by New Drug Products is Underway (JNJ, $65.15)

Investment Conclusion
JNJ has gone through three very difficult years as EPS increased only slightly from $4.63 in 2009 to $5.00…
Read more…

FDA Cardiovascular and Renal Advisory Committee Goes Against FDA View and Recommends Approval of Xarelto

The FDA had apparently slammed the door shut on approval of Johnson & Johnsonís Xarelto (rivaroxaban) for stroke prevention in…
Read more…

FDA Advisory Committee Goes Against FDA and Recommends Approval of Xarelto

The FDA had apparently slammed the door shut on approval of Johnson & Johnsonís Xarelto (rivaroxaban) for stroke prevention in…
Read more…

Hopes for Rivaroxaban Are Dashed (JNJ, $65.00)

 
Investment Opinion
The FDA problems encountered with rivaroxaban are a significant, but not crushing negative for the investment thesis of Johnson…
Read more…

Xarelto Could Be Another Blockbuster (JNJ, $66.64)

Introduction and Purpose of this Report
I believe that the anti-coagulant drug market is poised to become the next blockbuster category…
Read more…

Second Quarter Report Was Modestly Disappointing But New Pharmaceutical Products are the Key to the Investment Outlook (JNJ, $66.26)

Investment Thesis
There was modest investor disappointment with Johnson & Johnsonís second quarter results reported on July 19, 2011. The stock…
Read more…

Initial Buy Recommendation (JNJ, $62.69)

I believe that Johnson & Johnson will experience an acceleration in earnings based on an outstanding pipeline of new drugs.…
Read more…

Telaprevir Has Significant Therapeutic and Blockbuster Sales Potential for Hepatitis C (JNJ, $64.95)

The landscape for treating hepatitis C virus is on the verge of dramatic change due to the development of new…
Read more…

Abiraterone is Significant Advance in Prostate Cancer Treatment (JNJ, $64.11)

I recently recommended purchase of Johnson & Johnson (JNJ) in a report on April 24, 2010 called Johnson & Johnson…
Read more…

Hopes for Rivaroxaban Are Dashed (JNJ, $65.00)

Investment Opinion
The FDA problems encountered with rivaroxaban are a significant, but not crushing negative for the investment thesis of Johnson…
Read more…